ALXO - Company ID 0001810182
ALX ONCOLOGY HOLDINGS INC trades as ALXO. This page tracks ALX ONCOLOGY HOLDINGS INC through 409 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Net profit margin compressed from -664.3% to -3869.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-27 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
| SCHEDULE 13G/A | - | 2026-04-28 |
| Annual report to shareholders | ARS | 2026-04-20 |
| Proxy statement | DEF 14A | 2026-04-20 |
The largest companies sharing ALX ONCOLOGY HOLDINGS INC's SEC industry classification (pharmaceutical preparations).
In its latest fiscal year ALX ONCOLOGY HOLDINGS INC reported a net loss of $101.69M.